Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Fineline Cube Aug 7, 2026
Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Fineline Cube Aug 7, 2026
Company Drug

Kelun-Biotech’s SKB264 Approved for Phase II Study in EGFR-Mutant NSCLC

Fineline Cube Jan 12, 2023

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the National Medical Products...

Company

BeiGene Outlines Global R&D Strategy at J.P. Morgan Healthcare Summit

Fineline Cube Jan 12, 2023

China-based biotech BeiGene (Nasdaq: BGNE, HKG: 6160) provided an update on its company strategy and...

Company Deals

Evopoint Biosciences Licenses SOS1 Inhibitor to METiS Therapeutics

Fineline Cube Jan 11, 2023

China-based Evopoint Biosciences has announced a global licensing agreement with US firm METiS Therapeutics Inc.,...

Company Drug

Pfizer’s Nurtec ODT Launches in China via Hainan’s Bo’Ao Lecheng Zone

Fineline Cube Jan 11, 2023

US-based Pfizer’s (NYSE: PFE) Nurtec ODT (rimegepant), the world’s first calcitonin gene-related peptide (CGRP) receptor...

Company Deals

HKEX 2022 Annual Report: IPO Activity Declines Amid Global Challenges

Fineline Cube Jan 11, 2023

The Hong Kong Exchanges and Clearing Ltd (HKEX) has released its annual report for 2022,...

Company Drug

Konruns Initiates Phase II Study for KC1036 in Advanced Thymic Tumors

Fineline Cube Jan 11, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced the initiation of a single-arm, open,...

Company Drug

Dizal’s Sunvozertinib NDA Accepted for Review by China’s NMPA

Fineline Cube Jan 11, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its New Drug Application (NDA)...

Company Drug

HighTide Therapeutics Doses First Patient in Phase IIb Study for HTD1801 in NASH

Fineline Cube Jan 11, 2023

Shenzhen-based HighTide Therapeutics Inc. has announced that the first patient has been dosed in a...

Drug

MSD Submits Initial Quotation for Molnupiravir in China Amid New COVID-19 Rules

Fineline Cube Jan 11, 2023

Under new rules specifically for the launch of COVID-19 therapeutics in China, US-based Merck Sharp...

Company Drug

Treadwell Therapeutics’ CFI-402257 Granted Fast-Track Status by FDA

Fineline Cube Jan 11, 2023

China-based clinical-stage biotech Treadwell Therapeutics has announced receiving fast-track status from the US Food and...

Policy / Regulatory

CDE Releases 66th Batch of Chemical Generic Reference Preparations

Fineline Cube Jan 11, 2023

The Center for Drug Evaluation (CDE) has released the 66th batch of chemical generic reference...

Company Drug

Jiangsu Kanion’s KYS202002A Greenlit for Clinical Study in Multiple Myeloma

Fineline Cube Jan 11, 2023

China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving approval from the National...

Company Deals

Gaoling Medical Secures Funding for Infrared Thermotherapy Technology

Fineline Cube Jan 11, 2023

Gaoling Medical, a Hangzhou-based developer of systemic infrared thermotherapy technology, has raised an undisclosed amount...

Company Drug

Yiling Pharmaceutical’s BIO-008 Accepted for Review by China’s NMPA

Fineline Cube Jan 11, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that its clinical trial filing for...

Company Deals

Sino Biopharmaceutical Secures Rights to Biosimilar of Amgen’s Xgeva in China

Fineline Cube Jan 11, 2023

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary CP Pharmaceutical Qingdao has...

Company Deals

CanSino Biologics to Issue GDRs on SWX Swiss Exchange to Boost Globalization

Fineline Cube Jan 11, 2023

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced plans to issue an undisclosed amount...

Company Drug

Luye Pharma Launches Named Patient Program for Lurbinectedin in Hong Kong

Fineline Cube Jan 11, 2023

China-based Luye Pharma Group (HKG: 2186) has announced the launch of a Named Patient Program...

Company Drug

Innovent Biologics Doses First Patient in Phase III Study for Mazdutide

Fineline Cube Jan 10, 2023

China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the first patient has been dosed...

Policy / Regulatory

China Meheco Keyi Pharma’s Ganciclovir Loses VBP Bid After Inspection Failure

Fineline Cube Jan 10, 2023

The national drug alliance procurement office has released a notification indicating that China Meheco Keyi...

Policy / Regulatory

NMPA Releases 63rd Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Jan 10, 2023

The National Medical Products Administration (NMPA) has released the 63rd batch of reference drugs for...

Posts pagination

1 … 614 615 616 … 705

Recent updates

  • CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma
  • Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction
  • Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months
  • Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis
  • Westlake Consortium Secures NMPA Approval for Iscartrelvir, Novel Oral 3CLpro Inhibitor for Mild-to-Moderate COVID-19
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Company Drug

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.